Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
0.400
+0.018 (4.68%)
At close: Dec 20, 2024, 4:00 PM
0.399
-0.001 (-0.15%)
After-hours: Dec 20, 2024, 5:59 PM EST
Spruce Biosciences Stock Forecast
SPRB's stock price has decreased by -74.36% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Spruce Biosciences stock have an average target of 2.17, with a low estimate of 1.50 and a high estimate of 3.00. The average target predicts an increase of 442.50% from the current stock price of 0.40.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for SPRB stock from 7 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 0 |
| Hold | 5 | 5 | 5 | 5 | 5 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Dec 16, 2024 |
| Guggenheim | Guggenheim | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Dec 12, 2024 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades $3 | Buy → Hold | Downgrades | $3 | +650.00% | Dec 11, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $2 → $1.5 | Hold | Reiterates | $2 → $1.5 | +275.00% | Dec 11, 2024 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 11, 2024 |
Financial Forecast
Revenue This Year
5.04M
from 10.09M
Decreased by -50.01%
Revenue Next Year
1.63M
from 5.04M
Decreased by -67.64%
EPS This Year
-0.96
from -1.24
EPS Next Year
-0.57
from -0.96
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 7.4M | 6.3M | 12.1M | |||
| Avg | 5.0M | 1.6M | 4.2M | |||
| Low | 4.1M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -26.2% | 24.9% | 639.9% | |||
| Avg | -50.0% | -67.6% | 157.8% | |||
| Low | -59.2% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.91 | -0.28 | -0.18 | |||
| Avg | -0.96 | -0.57 | -0.61 | |||
| Low | -0.97 | -0.90 | -1.45 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.